

JT12 Rec'd PCT/PTO 22 JUL 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-64141-02
	Application Number	
	Filed	Herewith
	First Named Inventor	Harris
	Art Unit	
	Examiner Name	

**U.S. PATENT DOCUMENTS**

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
	MH	5,965,398	12 Oct 1999	Garkavtsev <i>et al.</i>
		6,066,474	23 May 2000	Marcu
		6,117,633	12 Sep 2000	Garkavtsev <i>et al.</i>
		6,238,918	29 May 2001	Garkavtsev <i>et al.</i>
		2004/0058379	25 March 2004	Harris <i>et al.</i>
	↓	2004/0115747	17 June 2004	Harris <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
	MH	WIPO	WO 01/36476	25 May 2001	Rigel Pharmaceuticals, Inc.
	MH	WIPO	WO 01/47959	5 July 2001	Jager <i>et al.</i>

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
	MH	Garkavtsev <i>et al.</i> , "Suppression of the Novel Growth Inhibitor p33 <sup>ING1</sup> Promotes Neoplastic Transformation," <i>Nature Genetics</i> 14:415-420, 1996
	MH	Garkavtsev <i>et al.</i> , "Extension of the Replicative Life Span of Human Diploid Fibroblasts by Inhibition of the p33 <sup>ING1</sup> Candidate Tumor Suppressor," <i>Mol. Cell Biol.</i> 17(4):2014-2019, April 1997
	MH	Garkavtsev <i>et al.</i> , "The Candidate Tumour Suppressor p33 <sup>ING1</sup> Cooperates with p53 in Cell Growth Control," <i>Nature</i> 391:295-298, 1998

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

DT12 Rec'd PCT/PTO 22 JUL 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-64141-02
		Application Number	10/502431
		Filed	Herewith
		First Named Inventor	Harris
		Art Unit	
		Examiner Name	
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
MH		Loewith <i>et al.</i> , "Three Yeast Proteins Related to the Human Candidate Tumor Suppressor p33 <sup>ING1</sup> Are Associated with Histone Acetyltransferase Activities," <i>Mol. Cell Biol.</i> 20(11):3807-3816, June 2000	
		Zeremski <i>et al.</i> , "Structure and Regulation of the Mouse <i>ing1</i> Gene," <i>J. Biol. Chem</i> 274(45):32172-32181, 1999	
		GenBank Accession No. AAB82387, 25 October 1997, 2 pages	
		GenBank Accession No. AAD48585, 12 August 1999, 1 page	
		GenBank Accession No. AF110645, 12 August 1999, 2 pages	
		GenBank Accession No. AF189286, 30 January 2002, 2 pages	
		GenBank Accession No. AX147962, 8 June 2001, 1 page	
		GenBank Accession No. BC005370, 12 July 2001, 2 pages	
		GenBank Accession No. BG170225, 6 February 2001, 2 pages	
		GenBank Accession No. BG753113, 15 May 2001, 2 pages	
		GenBank Accession No. NM_032329, 19 May 2001, 2 pages	
		GenBank Accession No. NP_115705.1, 19 May 2001, 1 page	

<b>EXAMINER SIGNATURE:</b> /Mark Halvorson/	<b>DATE CONSIDERED:</b> 12/29/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	